WilmerHale Receives 2013 LMG Life Sciences “Canadian Impact Deals of the Year” Award

Download IconDownload Print IconPrint

WilmerHale Receives 2013 LMG Life Sciences “Canadian Impact Deals of the Year” Award

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Providing comprehensive solutions for the acquisition, enforcement and protection of IP.

By patenting their innovations, our clients increase the value of their intellectual property and enhance their ability to compete in the marketplace. We work with laboratory and research teams and R&D and product development groups to determine whether, when and where it is in our clients’ business and technical interests to seek patent protection. And we don’t just file patent applications. Drawing on our experience with patent litigation, corporate financings and technology transactions, we implement IP strategies that conserve resources, add measurable value and give our clients a cost-effective and commercially practical competitive edge.

We help clients obtain more than 750 US and foreign patents each year, covering innovations that span the technological spectrum, including aerospace, biochemistry, biotechnology, business methods, chemistry, computer science, fuel cells, genetics, high-speed data communication, integrated circuits, materials science, medical devices, nanotechnology, pharmaceuticals, semiconductor devices and processes, and software.

We also prepare and prosecute patent applications internationally under the Patent Cooperative Treaty and by working with a network of seasoned patent lawyers around the world. Our experience extends to appeals, interferences and opposition proceedings within the US Patent and Trademark Office, the US Court of Appeals for the Federal Circuit and the European Patent Office.

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
A global team handling highly complex and sensitive matters in all aspects of litigation.
Uncompromising defense of corporations and individuals in high-profile and complex litigation and investigations.

On September 25, WilmerHale was named as the winner of the LMG Life Sciences "Canadian Impact Deals of the Year" award at the LMG Life Sciences Awards dinner at the Essex House in New York City. The firm was recognized for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.-a cross-border deal valued at up to $1.8 billion and led by Partners Hal Leibowitz, Belinda Juran and Jeff Hermanson.

The award was given as part of LMG's inaugural awards program that is an offshoot of the LMG Life Sciences rankings published late last spring. WilmerHale received favorable results in the guidebook, including being named for the second consecutive year as a "Lifecycle Firm" in the United States-a classification that indicates that a firm is regarded as one of the best, full-service law firms within the life sciences industry.

In addition to receiving the "Canadian Impact Deal of the Year" award at last night's event, WilmerHale had been shortlisted as a "Firm of the Year" in several categories, including: Mergers & Acquisitions, Venture Capital, Financial & Transactional, Government Investigations, Hatch-Waxman (Branded), Patent Litigation and Intellectual Property. The firm also had three individuals shortlisted for the "Attorney of the Year" award: Bill Lee (Hatch-Waxman (Branded); Intellectual Property), David Redlick (Mergers  & Acquisitions; Financial & Transactional) and Steve Singer (Corporate Advisory; Venture Capital).

The life sciences industry is a significant part of WilmerHale's practice. The firm has represented life sciences clients in boardrooms and courtrooms across the United States and Europe for four decades. Representing public and private companies, investment banks and venture capitalists in all aspects of the life sciences industry, the firm's lawyers understand the business of these clients and the regulatory, competitive and consumer demands that the industry is currently confronting.

LMG Life Sciences' 2013 rankings and awards were developed based upon extensive industry-wide research, based on nearly 1,000 interviews and surveys completed by partners who are active in the market.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel